One study has shown that intraperitoneal administration of anti-CCL20 antibody has inhibited osteolytic breast cancer bone metastasis in a mouse model, and CCL20 has significantly enhanced cell invasion and secretion of matrix metalloproteinase (MMP) 2 and 9 in TNBC cell lines [40]. The gene discussed is CCL20; the disease is breast cancer.